Xiu-Bao Ren (Xiubao Ren)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 28

Top Topics

Metastatic Colorectal Cancer

Top Venues

Cancer biology & medicine

Cell death discovery

Signal transduction and targeted therapy

Cancer gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang, Wei-Hong Zhang, Jie-Yao Li, Xiao Zheng, Qi-Jing Wang, Yong-Qiang Li, Tong Xiang, Li Zhou, Shuang-Ning Yang, Chen Wu, Rong-Xing Huang, Jia He, Wei-Jiao Du, Lu-Jun Chen, Yue-Na Wu, Bin Xu, Qiong Shen, Yi Zhang, Jing-Ting Jiang, Xiu-Bao Ren, Jian-Chuan Xia
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. Signal transduction and targeted therapy 9 (1) (2024)
Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang, Wei-Hong Zhang, Jie-Yao Li, Xiao Zheng, Qi-Jing Wang, Yong-Qiang Li, Tong Xiang, Li Zhou, Shuang-Ning Yang, Chen Wu, Rong-Xing Huang, Jia He, Wei-Jiao Du, Lu-Jun Chen, Yue-Na Wu, Bin Xu, Qiong Shen, Yi Zhang, Jing-Ting Jiang, Xiu-Bao Ren, Jian-Chuan Xia
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. Signal transduction and targeted therapy 9 (1) (2024)
Jing Qin, Feng Wei, Xiu-Bao Ren
Neutrophils in the era of single-cell RNA sequencing: functions and targeted therapies in cancer. Cancer biology & medicine 20 (12) (2024)
Jing Qin, Feng Wei, Xiu-Bao Ren
Neutrophils in the era of single-cell RNA sequencing: functions and targeted therapies in cancer. Cancer biology & medicine 20 (12) (2024)
Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang, Wei-Hong Zhang, Jie-Yao Li, Xiao Zheng, Qi-Jing Wang, Yong-Qiang Li, Tong Xiang, Li Zhou, Shuang-Ning Yang, Chen Wu, Rong-Xing Huang, Jia He, Wei-Jiao Du, Lu-Jun Chen, Yue-Na Wu, Bin Xu, Qiong Shen, Yi Zhang, Jing-Ting Jiang, Xiu-Bao Ren, Jian-Chuan Xia
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. Signal transduction and targeted therapy 9 (1) (2024)
Jing Qin, Feng Wei, Xiu-Bao Ren
Neutrophils in the era of single-cell RNA sequencing: functions and targeted therapies in cancer. Cancer biology & medicine 20 (12) (2024)
Yanan Cui, Yanping Chen, Peiyan Zhao, Shuang Li, Ying Cheng, Xiu-Bao Ren
Peripheral NK cells identified as the predictor of response in extensive-stage small cell lung cancer patients treated with first-line immunotherapy plus chemotherapy. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
Li Li, Tao Xing, Yiran Chen, Weiran Xu, Bo Fan, Gaoda Ju, Jing Zhao, Li Lin, Cihui Yan, Jun Liang, Xiu-Bao Ren
In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma. Cell death discovery 9 (1) (2023)
Li Li, Tao Xing, Yiran Chen, Weiran Xu, Bo Fan, Gaoda Ju, Jing Zhao, Li Lin, Cihui Yan, Jun Liang, Xiu-Bao Ren
Correction: In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma. Cell death discovery 9 (1) (2023)
Li Li, Tao Xing, Yiran Chen, Weiran Xu, Bo Fan, Gaoda Ju, Jing Zhao, Li Lin, Cihui Yan, Jun Liang, Xiu-Bao Ren
Correction: In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma. Cell death discovery 9 (1) (2023)
Li Li, Tao Xing, Yiran Chen, Weiran Xu, Bo Fan, Gaoda Ju, Jing Zhao, Li Lin, Cihui Yan, Jun Liang, Xiu-Bao Ren
In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma. Cell death discovery 9 (1) (2023)
Zhenzhen Hui, Yulin Ren, Dong Zhang, Yulong Chen, Wenwen Yu, Jie Cao, Liang Liu, Tao Wang, Shanshan Xiao, Liuqing Zheng, Yue Pu, Feng Wei, Jian You, Xiu-Bao Ren
PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127 + and KLRG1 + CD8 T cells. NPJ precision oncology 7 (1) (2023)
Siyu Zhu, Chen Zhang, Qian Sun, Xiubao Ren, Wenwen Yu, Feng Wei, Xiu-Bao Ren
Trained Immunity of IL-12-, IL-15-, and IL-18-Induced CD 3 +CD 56 + NKT-Like Cells. Journal of oncology 2022 (2022)
Shaochuan Liu, Yuan Meng, Liang Liu, Yingge Lv, Feng Wei, Wenwen Yu, Limei Wang, Xiying Zhang, Xiu-Bao Ren, Qian Sun
Rational pemetrexed combined with CIK therapy plus anti-PD-1 mAbs administration sequence will effectively promote the efficacy of CIK therapy in non-small cell lung cancer. Cancer gene therapy (2022)
Xiu-Bao Ren
Cancer immunology and immunotherapy. Cancer biology & medicine 18 (4) (2022)
Shaochuan Liu, Yuan Meng, Liang Liu, Yingge Lv, Wenwen Yu, Ting Liu, Limei Wang, Di Mu, Qiuru Zhou, Min Liu, Yulin Ren, Dong Zhang, Baihui Li, Qian Sun, Xiu-Bao Ren
CD4 + T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer. Cell death & disease 13 (5) (2022)
Fan Kou, Lei Wu, Ye Zhu, Baihui Li, Ziqi Huang, Xiu-Bao Ren, Lili Yang
Somatic copy number alteration predicts clinical benefit of lung adenocarcinoma patients treated with cytokine-induced killer plus chemotherapy. Cancer gene therapy 29 (8-9) (2022)
Zhenzhen Hui, Jiali Zhang, Yulin Ren, Xiaoling Li, Cihui Yan, Wenwen Yu, Tao Wang, Shanshan Xiao, Yulong Chen, Ran Zhang, Feng Wei, Jian You, Xiu-Bao Ren
Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC). Cell death & disease 13 (7) (2022)
Yang Yang, Wei Pang, Hongxiang Zhang, Weiwei Cui, Ke Jin, Chongling Sun, Yanyan Wang, Lin Zhang, Xiu-Bao Ren, Xuexin Duan
Manipulation of single cells via a Stereo Acoustic Streaming Tunnel (SteAST). Microsystems & nanoengineering 8 (2022)
Fengying Wu, Tao Jiang, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, Qiming Wang, Ying Cheng, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, LiPing Wang, Jianhua Chang, Qun Chen, Xiu-Bao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, Xiaorong Dong, Tao Zhang, Wei Shi, Jianjun Zou, Xuejuan Bai, Shengxiang Ren, Caicun Zhou, null null
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy. Cancer communications (London, England) (2022)
Min Liu, Qian Sun, Feng Wei, Xiu-Bao Ren
Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors. Cancer biology & medicine 17 (3) (2021)
Kaiyuan Wang, Jian Wang, Ting Liu, Wenwen Yu, Nan Dong, Chen Zhang, Wenbin Xia, Feng Wei, Lili Yang, Xiu-Bao Ren
Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer. Cancer biology & medicine 18 (1) (2021)
Weihong Zhang, Yuan Meng, Lin Yang, Meng Shen, Li Zhou, Runmei Li, Yang Wang, Weijiao Du, Yanjuan Xiong, Ying Han, Xinwei Zhang, Liang Liu, Xiu-Bao Ren
Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events. Cancer biology & medicine (2021)
Hua Zhao, Hao Wang, Qiuru Zhou, Xiu-Bao Ren
Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies. Cancer biology & medicine (2021)
Chen Zhang, Jie Yin, Jian Zheng, Jun Xiao, Jiajian Hu, Yudong Su, Kaichen Zhou, Yingchi Zhang, Xuzhen Zhang, Hong Zhang, Qian Sun, Yang Wang, Wenwen Yu, Feng Wei, Qiang Zhao, Long Li, Xiu-Bao Ren
EZH2 identifies the precursors of human natural killer cells with trained immunity. Cancer biology & medicine (2021)
Fan Kou, Lei Wu, Yan Guo, Bailu Zhang, Baihui Li, Ziqi Huang, Xiu-Bao Ren, Lili Yang
Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy. Cancer biology & medicine (2021)
Ziqing Zeng, Feng Wei, Xiu-Bao Ren
Exhausted T cells and epigenetic status. Cancer biology & medicine 17 (4) (2020)
Zhenzhen Hui, Feng Wei, Hongliang Ren, Wengui Xu, Xiu-Bao Ren
Primary tumor standardized uptake value (SUVmax) measured on 18F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer. Journal of cancer research and clinical oncology 146 (10) (2020)